Stock Events

Stock Events

Adaptive Biotechnologies 

$24.16
149
-$0.41-1.67% 14:48 Today

Statistics

Day High
24.39
Day Low
23.94
52W High
26.87
52W Low
12
Volume
17,097
Avg. Volume
-
Mkt Cap
3.86B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.29
-0.17
-0.06
0.06
Expected EPS
-0.0975
Actual EPS
N/A

Financials

-21.48%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
276.98MRevenue
-59.5MNet Income

Analyst Ratings

24.42Average Price Target
The highest estimate is 28.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADPT. It's not an investment recommendation.
Amazon
42
AMZN
NVIDIA
40
NVDA
Apple
29
AAPL
Microsoft
28
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap32.55B
Illumina provides genomic sequencing solutions and competes with Adaptive Biotechnologies in the genomic analysis market.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers long-read sequencing technologies that compete with Adaptive's platforms for comprehensive genomic profiling.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a field that overlaps with Adaptive's focus on leveraging genetic information for medical solutions.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the gene editing space, competing with Adaptive in the development of genetically informed therapies.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing industry, directly competing with Adaptive Biotechnologies in the pursuit of personalized medicine solutions.
Guardant Health
GH
Mkt Cap21.67B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing with Adaptive in the oncology diagnostics market.
Bionano Genomics
BNGO
Mkt Cap13.78M
Bionano Genomics offers genomic analysis tools, competing with Adaptive in the market for genetic research and clinical applications.

About

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Show more...
CEO
Chad Robins
Employees
624
Country
United States
ISIN
US00650F1093
WKN
000A2PLR5

Listings

STU
DE
1HM.STU
XNAS
US
ADPT
MU
DE
1HM.MU
F
DE
1HM.F

0 Comments

Share your thoughts

FAQ

What is Adaptive Biotechnologies stock price today?▼
The current price of ADPT is $24.16 USD — it has decreased by -1.67% in the past 24 hours. Watch Adaptive Biotechnologies stock price performance more closely on the chart.
What is Adaptive Biotechnologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Adaptive Biotechnologies stocks are traded under the ticker ADPT.
Is Adaptive Biotechnologies stock price growing?▼
ADPT stock has fallen by -4.76% compared to the previous week, the month change is a -2.28% fall, over the last year Adaptive Biotechnologies has showed a +84.25% increase.
What is Adaptive Biotechnologies market cap?▼
Today Adaptive Biotechnologies has the market capitalization of 3.86B
When is the next Adaptive Biotechnologies earnings date?▼
Adaptive Biotechnologies is going to release the next earnings report on November 05, 2026.
What were Adaptive Biotechnologies earnings last quarter?▼
ADPT earnings for the last quarter are -0.25 USD per share, whereas the estimation was -0.13 USD resulting in a -87.12% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adaptive Biotechnologies revenue for the last year?▼
Adaptive Biotechnologies revenue for the last year amounts to 276.98M USD.
What is Adaptive Biotechnologies net income for the last year?▼
ADPT net income for the last year is -59.5M USD.
How many employees does Adaptive Biotechnologies have?▼
As of September 04, 2026, the company has 624 employees.
In which sector is Adaptive Biotechnologies located?▼
Adaptive Biotechnologies operates in the Health & Wellness sector.
When did Adaptive Biotechnologies complete a stock split?▼
Adaptive Biotechnologies has not had any recent stock splits.
Where is Adaptive Biotechnologies headquartered?▼
Adaptive Biotechnologies is headquartered in SEATTLE, United States.